Dr. Robert Grant, a seasoned HIV researcher who developed PrEP, and Donald G. McNeil Jr., a veteran health reporter, discuss the potential of a groundbreaking drug to end the HIV epidemic. They explore the promising results of Truvada, yet highlight challenges such as its high cost and access issues. The conversation reveals the complexities surrounding pharmaceutical practices, including Gilead's initiatives for broader access, and the critical role of journalism in advocating for equitable treatment. It's a candid look at the intersection of science, profit, and public health.
